Therapeutics based on nucleic acids (NA) promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods. We have recently developed a new NA delivery platform based on polymeric CXCR4 inhibitors (PCX) suitable as dual-function systems for simultaneous NA delivery and inhibition of CXCR4 chemokine receptor. The objective of this 1-year Phase I project is to use the PCX platform to develop an innovative combination treatment of cholangiocarcinoma using PCX/microRNA nanoparticles. Clinical and experimental studies show that CXCR4 expression is associated with more aggressive disease, higher primary tumor burden, more metastases, and shorter overall survival in cholangiocarcinoma. The hypothesis of this project is that using PCX to deliver miR106b inhibitor, identified in our preliminary studies s potential target in cholangiocarcinoma, will lead to improved overall anticancer activity. We will accomplish the objectives through pursuing the following specific aims: 1) optimize PCX/microRNA formulation parameters to obtain nanoparticles capable of simultaneous CXCR4 inhibition and microRNA delivery in cholangiocarcinoma and 2) determine if delivery of miR106b inhibitor by PCX improves overall survival in orthotopic rat model of cholangiocarcinoma. The approach is innovative because of the dual-function design of nanoparticles with CXCR4 inhibitory activity and microRNA delivery. The proposed research is significant because it will establish widely applicable and versatile NA delivery platform that target chemokine networks as a way of improving therapeutic outcomes in cancer and other diseases with involvement of CXCR4.
Public Health Relevance Statement: Public Health Relevance: Nucleic acids represent a class of promising therapeutic agents in a broad range of diseases. To take full advantage of these new therapeutics, there is a critical need to develop reliable and efficient delivery methods. The proposed research is relevant to public health because it will address the need for such methods by developing unique dual-function nanoparticles to deliver microRNA as a way of treating a deadly form of liver cancer.
NIH Spending Category: Bioengineering; Biotechnology; Cancer; Digestive Diseases; Digestive Diseases - (Gallbladder); Liver Cancer; Liver Disease; Nanotechnology; Orphan Drug; Rare Diseases
Project Terms: Address; Adjuvant; anticancer activity; base; cancer type; Characteristics; chemokine; chemokine receptor; chemotherapy; Cholangiocarcinoma; Clinical Research; Combined Modality Therapy; Complex; CXCR4 gene; design; Development; Disease; DNA; Exhibits; Family; Formulation; Generations; Goals; Histocompatibility Testing; human disease; improved; In Vitro; in vivo; Incidence; Inflammatory; Inflammatory Bowel Diseases; inhibitor/antagonist; innovation; Lead; Liver neoplasms; malignant breast neoplasm; Malignant neoplasm of liver; Malignant Neoplasms; Medical; melanoma; Mendelian disorder; Methods; MicroRNAs; Modeling; mortality; nanoparticle; Neoadjuvant Therapy; Neoplasm Metastasis; novel; novel strategies; novel therapeutics; nucleic acid inhibitor; Nucleic Acids; Patients; Pharmacologic Substance; Phase; physical property; Play; Positioning Attribute; pre-clinical; Preparation; Primary Neoplasm; Psoriasis; Public Health; public health relevance; Quality of life; Rattus; Research; research study; Resistance; Rodent; Role; Safety; safety study; Small Interfering RNA; standard of care; success; System; Technology; Testing; Therapeutic; Therapeutic Agents; therapeutic miRNA; therapy outcome; Tissues; treatment strategy; Tumor Burden; vector; Work
